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ABSTRACT
Current advances in the study of cutaneous adverse drug reactions can be attributed to the recent under-
standing that the skin is both a metabolically and immunologically competent organ. The ability of the
skin to serve as a protective barrier with limited drug biotransformation ability, yet highly active immune
function, has provided insights into its biological capability. While the immune response of the skin to
drugs is vastly different from that of the liver due to evolutionary conditioning, it frequently occurs in
response to various drug classes and manifests as a spectrum of hypersensitivity reactions. The skin is a
common site of adverse and idiosyncratic drug reactions; drug-specific T-cells, as well as involvement of
an innate immune response, appear to be key mechanistic drivers in such scenarios. Association of other
factors such as human leukocyte antigen (HLA) polymorphisms may play a significant role for particular
drugs. This review aims to integrate emerging findings into proposed mechanisms of drug metabolism
and immunity in the skin that are likely responsible for rashes and other local allergic responses. These
unique biological aspects of the skin, and their translation into implications for drug development and
the use of animal models, will be discussed.
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Recent advances in the knowledge of skin immunology and
enzymatic ability have reshaped our understanding of the skin
and its ability to respond to drugs and other foreign materials.
Current evidence strongly suggests that most skin rashes are
immune-mediated. In many cases, the immune response appears
to be triggered by a chemically reactive drug or a reactive metab-
olite. Though the skin has limited ability to metabolize drugs
(sulfotransferase and acetyltransferase have the greatest activity
with only limited cytochrome P450 activity), the immune activity
is quite high. Animal models are an essential tool to test hypoth-
eses, and have enabled an understanding of the relationship
between the metabolic capability and immunology of the skin.
One of the few animal models of drug-induced skin rash is due
to nevirapine in rats, which will be described in this review. This
model highlights many of the unique physiologic features of the
skin and demonstrates what chemical species is responsible for
the rash, namely a reactive sulfate metabolite formed in the skin.
However, other drugs that cause skin rashes in humans do not
generally cause skin rashes in animals; the dominant response
appears to be immune tolerance. Therefore, it may be possible to
produce other animal models of drug-induced skin rash by
impairing immune tolerance.
Drugs can induce a wide variety of skin reactions.
Maculopapular exanthema (MPE) and erythema multiforme
(EM) are common drug-induced skin rashes. Severe cutaneous
adverse reactions (SCAR) are life-threatening drug hypersensitiv-
ity responses, carrying high mortality and morbidity. SCARs
include drug-induced hypersensitivity syndrome (DIHS), drug
reaction with eosinophilia and systemic symptoms (DRESS),
Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis
(TEN) (Duong et al. 2017). Most reactions are likely allergic in
nature, and thus hard to evaluate with animals in the non-clin-
ical stage. The following further describes these clinically import-
ant types of skin reactions.
MPE is characterized by various erythema or papular erup-
tions, which are diffusely distributed on the body (Fernandez
et al. 2009). Erythema is relatively homogeneous and divided
into epidermal and dermal types. In the lesion, infiltration of
lymphocytes is observed. MPE often occurs from 1–2w following
drug administration, and can be due to diverse drugs such as
antibiotics (e.g. penicillin and sulfa drugs), antiepileptics (carba-
mazepine), allopurinol, or non-steroidal anti-inflammatory drugs
(NSAID). This is a mild type of skin reaction and often resolves
on stopping the medication.
EM is a skin disorder with a multiform of target lesions (usu-
ally three layers) with no or mild mucosal enanthema, and is
due to diverse causes, including herpes simplex virus and various
drugs (Lamoreux et al. 2006). EM can be divided into EM minor
(in which lesions are limited to the face and four limbs) and EM
major (with multiple lesions and fever). EM major leads to
erythroderma by fusion of the lesions and may involve internal
organ failure. EM is likely a delayed-type hypersensitivity reac-
tion, and T-cell infiltration into the skin is often observed.
DIHS is often diagnosed by high-fever, maculopapular rash,
involvement of at least one internal organ (mainly liver), blood
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abnormalities (lymphocytosis, eosinophilia, atypical lympho-
cyte), lymphadenopathy, and human herpesvirus six reactivation
(Shiohara et al. 2006). DRESS show similar symptoms, but have
different diagnostic criteria such as no viral re-activation (Lally
and Turner 2007). DIHS develops from 2–6week after drug
administration, and is due to limited drugs (i.e. antiepileptics,
allopurinol, sulfa drugs, mexiletine, and minocycline), and
requires hospitalization, with outcomes of high mortality (10%)
and increases of the chemokine TARC/CCL17 in blood.
SJS/TEN represents the most severe forms of skin reactions
(Duong et al. 2017). SJS/TEN show symptoms of wide-spread
blistering exanthema, high fever, and, in SJS, mucosal injury.
SJS/TEN are thought to be similar disorders classified by skin
detachment/blistering among areas of the epidermis: < 10% of
body surface area (BSA); SJS, 10%–30% of BSA; SJS/TEN over-
lap, and  30% of BSA:TEN. These reactions are very rare (1–5
cases/yr/1 million subjects) and develop within several days to
weeks after initiating the drug. Patients suffering from SJS/TEN
are hospitalized, and mortality rates are relatively high (SJS:
1–5%, TEN: 20–30%). Even after recovery, patients may suffer
sequela, such as vision loss due to pseudo-membrane formation
(Duong et al. 2017).
The lymphocyte transformation test (LTT, also drug-induced
lymphocyte stimulation test) is one of the clinical tests used for
investigating the suspected drugs. It detects proliferation of cir-
culating drug-specific memory T-cells, and its sensitivity is rela-
tively high (60–70%), particularly for DIHS, and MPE, but not
for TEN (Pichler and Tilch 2004). As its sensitivity is high but
specificity is not, positive results mean this drug is probably
causative, but negative results do not imply exclusion of the drug
as the causal agent.
Immune responses of the skin to drugs
The adaptive immune response: Overview
The immune system is quite complex, and while there are simi-
larities between immune responses in the skin and other organs,
there are also differences. A major difference between the
immune response in the skin versus the liver is that the domin-
ant immune response in the liver is immune tolerance. This is
illustrated by the difference in the ease of transplanting liver and
skin (Calne et al. 1969). Many cells are involved in dermal
immune responses, including ab and cd T-cells, natural killer
(NK) cells, B-cells, mast cells, and macrophages (Di Meglio et al.
2011). In addition, Langerhans cells (which express langerin) are
a unique antigen-presenting cell (APC) in the skin. The APC are
essential for initiation of an adaptive immune response.
Originally, APC were thought to be responsible for initiating
most immune responses in the skin. However, as it then been
found that there are other cells that express langerin, including
dermal dendritic cells (DC) (Clausen and Stoitzner 2015). Such
DC appear to be required for T-cell-mediated immune responses
in the skin.
Co-stimulatory and co-inhibitory pathways signal simultan-
eously to regulate whether antigen exposure will lead to T-cell
activation. Danger signals released as a result of cell stress due to
direct drug toxicity are an important stimulus for the up-regula-
tion of co-stimulatory ligands on APC (Gallucci and Matzinger
2001). Similarly, it has been shown that dysregulated co-inhibi-
tory receptor signaling can propagate autoimmunity (Chuang
et al. 2005), and that blocking these pathways (such as PD-1 and
CTLA-4) in cancer models can significantly enhance functional
T-cell responses (Kouki et al. 2000; Hodi et al. 2010).
As discussed above, drug exposure can result in an array of
cutaneous hypersensitivity reactions that vary in severity. Mild-
to-moderate conditions, such as MPE, involve the preferential
activation of perforin-producing CD4 T-cells, and in the case of
b-lactam reactions, T-helper (TH)-22 cells play a dominant role
(Castrejon et al. 2010; Whitaker et al. 2011; Sullivan et al. 2018).
In contrast, urticaria is mediated by plasma cell-generated IgE
antibodies, and pustular exanthema is mediated by neutrophils
(Pichler 2003).
Various SCAR develop more rapidly and severely after the
first episode in recurrent patients, suggesting that the pathogen-
esis of SCAR involves an immune memory response. The skin
lesions of SCAR show infiltration of immune cells, in which, SJS
and TEN have predominately CD8 T-cells and NK cells (Nassif
et al. 2004; Wei et al. 2012; Yun et al. 2013; Cho et al. 2014).
CD8 T-cells (also known as cytotoxic T-cells; CTL) have been
shown to produce cytokines (e.g. interleukin [IL]-15 and IL-2),
chemokines, and cytotoxic proteins (e.g. granulysin and gran-
zyme B), to induce cutaneous inflammation and kill keratino-
cytes in SJS/TEN (Chung et al. 2008; Su et al. 2017). With the
exception of abacavir, certain drugs can activate CD4 and CD8
T-cells in all hypersensitive patients (Pichler 2003; Adam et al.
2012; Lucas et al. 2015).
Proposed mechanisms for drug-induced hypersensitivity
reactions in the skin
Three models have been proposed to examine the antigenicity of
small-molecule drugs (Chung et al. 2016). The first is the hapten
hypothesis, which goes back many years to the work of
Landsteiner and Jacobs (1935) who found that small molecules
did not generally induce an immune response unless they cova-
lently bound to proteins and thus formed an altered or “foreign”
protein. However, foreign proteins do not provoke much of an
immune response in the absence of activation of APC. This led
to the second hypothesis, namely the danger hypothesis proposed
by Matzinger (1998), which stated that unless something was
causing damage and triggered an innate sense of danger, the
immune system ignored it. This damage could lead to produc-
tion of danger-associated molecular pattern (DAMP) molecules
that activate APC. Therefore, the hapten and danger hypotheses
are complementary.
The third hypothesis stems from a concept of interaction of
drugs with immune receptors that do not involve a reactive
metabolite and includes two models: the pharmacological inter-
action (p–i) model and the altered peptide repertoire model
(Pichler 2002). The p–i model proposes that a drug or its metab-
olite directly and non-covalently binds to the human leukocyte
antigen (HLA) molecule on APC in a region exposed to T-cells.
In this model, antigen processing (generation of drug-self peptide
complex) in APC can be bypassed. For example, carbamazepine
was shown to bind the HLA-B15:02 protein and induce CTL-
mediated keratinocyte lysis, supporting this model (Wei et al.
2012). The altered peptide repertoire model, although distinct
from the p–i model, is closely related and therefore discussed
along with the p–i model. It postulates that the drug strongly
binds to the cleft of a HLA molecule and alters the repertoire of
the self-peptides presented by the HLA protein to T-cells. The
anti-HIV drug abacavir was suggested to bind strongly to its
associated HLA-B57:01 protein and change the bound self-pep-
tide (Illing et al. 2012).
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Activation of the immune system based on any of these three
hypotheses involves the classical sensitization and elicitation
mechanism by which drugs presented by APC sensitize TH cells
first, and then CTL are activated to induce keratinocyte damage
through recognition of HLA-class I-drug complex. However
recently, the heterologous immunity model was raised (White
et al. 2015). This hypothesis proposes that virus-specific T-cells
may cross-react with drug-bound peptide-HLA complexes to ini-
tiate the immune response. As intrinsic T-cells against viruses
can react with the drug complex, the sensitization process may
be skipped in this model. This may explain the occasional rapid
onset of a rash on first exposure to a drug.
Other mechanistic hypotheses include mitochondrial injury,
unfolded protein response, and the inflammogen hypotheses,
which may or may not involve a reactive metabolite (Cho and
Uetrecht 2017). These effects could directly cause idiosyncratic
drug reactions (IDR) or lead to the production of various DAMP
that promote an immune response.
Although the mechanistic progress has been striking in this
area, several obstacles still exist for the prediction of skin tox-
icity/adverse reactions. First, knowledge of pathophysiological
mechanisms is still scarce to explain the diverse types of adverse
skin reactions. To solve this problem, greater mechanistic under-
standing is clearly necessary. Second, most adverse skin reactions
are thought to be immune- or metabolism-mediated (at least
partly), and thus, human-specific. Therefore, it is difficult to pre-
dict skin reactions using animal models, and thus proper in vitro
or transgenic animal models are warranted based on mecha-
nisms. Third, the predictability of the currently used LTT is
insufficient to find a true causative drug. New diagnostic meth-
ods are warranted considering the mechanisms.
Molecular interaction between drugs and HLA/TCR in SJS
and TEN
As HLA is the most polymorphic gene in the human genome,
and has the ability to present antigens to activate T-cells, HLA
has been proposed to be the risk factor of SCAR. The previous
studies of Chung et al. (2004) and Hung et al. (2005) first dis-
covered the strong HLA genetic predisposition to SCAR in Han
Chinese, which included (1) HLA-B15:02 and carbamazepine-,
or oxcarbazepine-induced SJS/TEN (Chung et al. 2004; Chen
et al. 2017), (2) HLA-B58:01 and allopurinol-induced SCAR
(Hung et al. 2005), and (3) HLA-A31:01 and carbamazepine-
induced DRESS and maculopapular eruption (Tate et al. 2006).
These genetic associations were validated in different populations
around the world (Lonjou et al. 2008; Tassaneeyakul et al. 2009;
McCormack et al. 2011; Genin et al. 2014). In addition, there are
increasing reports showing that drug hypersensitivity has strong
HLA genetic predisposition, for example, abacavir hypersensitiv-
ity and HLA-B57:01 (Mallal et al. 2002), and dapsone hypersen-
sitivity and HLA-B13:01. (Zhang et al. 2013). Table 1 shows
examples of HLA types reported to be associated with specific
drug-induced SCARs in the ethnic populations (Kaniwa and
Saito 2013; Chung et al. 2016). Based on these scientific reports,
HLA markers are described in drug labels in several countries.
Table 2 displays a description of HLA marker types in carba-
mazepine labels.
In addition to the immune determinant HLA genes, cyto-
chrome P 2C9 (CYP2C9) variants causing defects of drug
metabolism were shown to be strongly associated with pheny-
toin-induced SCAR (Chung and Hung 2014). The defects of
drug metabolism or clearance could also be due to renal defi-
ciency in allopurinol-SCAR patients, and both genetic defi-
ciency and underlying disease can lead to the accumulation of
drug antigens (Chung and Hung 2014; Chung et al. 2015;
Yang et al. 2015; Ng et al. 2016). The delayed drug clearance
was associated with increased serum levels of granulysin, and
high mortality within SCAR patients (Chung et al. 2015; Yang
et al. 2015; Ng et al. 2016). As the strength of association is
strong, numerous genetic markers have been applied in clinics
to prescreen patients and identify genes that may indicate a
predisposition to SCAR (Mallal et al. 2008; Chen et al. 2011;
Pan et al. 2017).
Table 1. Examples of associated HLA types with SCARs.
Types Drugs SCARs Ethnics
HLA-B15:02 Carbamazepine SJS/TEN Han Chinese, Thai, Malay, and Indian
HLA-B15:11 Carbamazepine SJS/TEN Japanese, Korean, and Han Chinese
HLA-A31:01 Carbamazepine SJS/TEN/DIHS/DRESS/MPE Han Chinese, Caucasian, Japanese, and Korean
HLA-B58:01 Allopurinol SJS/TEN/HSS (inc. DIHS/DRESS) Han Chinese, Thai, Malay, Korean, Caucasian, and Japanese
HLA-B57:01 Abacavir HSS Caucasian, African, Thai, and Cambodian
HLA-A02:06 Cold medicine SJS/TEN Japanese and Korean
HLA-B15:02-C08:01 haplotype Sulfamethoxazole/Trimethoprim SJS/TEN Thai
HLA-B35:05 Nevirapine Skin reaction Thai
HLA-B59:01 Methazolamide SJS/TEN Korean and Japanese
HSS: Hypersensitivity syndrome. Compiled from (Kaniwa and Saito 2013; Ueta et al. 2014; Kongpan et al. 2015; Chung et al. 2016)
Table 2. Description of HLA marker types in carbamazepine labels.
Drug HLA type Countrya/Area HLA testing in the package insert
Carbamazepine B15:02 USA Prior test should be performed in patients with ancestry in genetically at-risk populations (Asians)
Australia Prior test should be considered in patients with ancestry in genetically at-risk populations
Taiwan Prior test should be considered in patients with ancestry in Asian populations (reimbursed by health insurance)
Canada Test is recommended to be considered in genetically at-risk populations (Asians)
Singapore Testing is highly recommended in patients with Asian ancestry
Japan Reminded
A31:01 Australia Prior test should be considered in patients with ancestry in genetically at-risk populations
Canada Test is recommended to be considered in genetically at-risk populations
USA The risks and benefits of carbamazepine therapy should be weighed in patients known to be positive with this allele
Taiwan Presence of HLA-A31:01 should be considered prior to initiation of treatment
Japan Reminded
ahttps://www.accessdata.fda.gov/drugsatfda, https://www.ebs.tga.gov.au, https://www.fda.gov.tw, https://pdf.hres.ca, https://eservice.hsa.gov.sg, http://www.pmda.
go.jp
JOURNAL OF IMMUNOTOXICOLOGY 3
The HLA and CYP predisposition observed in drug hypersen-
sitivity are not only genetic markers, but play immunotoxicologic
functional roles in the pathogenesis of SCAR. By applying mass
spectrometry, Yang et al. (2007) reported that there was no
detection of specific carbamazepine-modified peptides with
HLA-B15:02 protein. Wei et al. (2012) reported that endogen-
ous peptide-loaded HLA-B15:02 molecules presented carba-
mazepine to CTL without involvement of intracellular drug
metabolism or antigen processing. The HLA-B15:02-peptide-b2-
microglobulin protein complex exhibited binding affinity toward
chemicals with 5-carboxa-mide on the tricyclic ring, such as
carbamazepine and oxcarbazepine. HLA-B75 family members
share a structure similar to that of HLA-B15:02, and could also
present carbamazepine to activate CTL cells. Three residues
(Asn63, Ile95, and Leu156) in the peptide-binding groove of
HLA-B15:02 were involved in carbamazepine presentation and
CTL activation. In particular, Asn63 shared by members of
the B75 family was seen to be the key residue. Computer
simulations revealed a preferred molecular conformation of the 5-
carboxamide group of carbamazepine and the sidechain of Arg62
on the B pocket of HLA-B15:02. Furthermore, prefer-ential
T-cell receptor (TCR)-Vb and TCR-Va usages and oligo-clonal
expansion of TCR were identified in the ex vivo drug-expanded
cultures of peripheral blood mononuclear cells (PBMC) of
patients with carbamazepine-induced SJS/TEN (Ko et al. 2011).
That study showed that the expression of TCR was drug-specific
and phenotype-specific, and that TCR transfectants showed an
immune response to the drug in a HLA-restricted manner.
Binding of the allopurinol metabolite, oxypurinol, to HLA-
B58:01 molecule was also identified by T-cell proliferation
assays and in silico analysis (Lin et al. 2015). A high concentra-
tion of oxypurinol stimulated the T-cells of PBMC of patients
with allopurinol-SCAR to produce granulysin and granzyme B
(Chung et al. 2015). The Arg97 located between the E and C
pocket of HLA-B58:01 was identified as a key residue for oxy-
purinol binding (Lin et al. 2015). Furthermore, the technology of
next-generation sequencing was applied to study TCR clonotypes
of allopurinol-induced SCAR (Chung et al. 2015). Preferential
TCR-V-b usage and clonal expansion of specific CDR3 (third
complementarity-determining region) were identified in blister
cells from skin lesions and oxypurinol-activated T-cells from
allopurinol-SCAR patients (Chung et al. 2015).
In summary, these molecular and functional studies on carba-
mazepine and allopurinol revealed that in susceptible subjects,
the plasma levels of drug antigens increased due to the defects of
drug metabolism, and the genetically associated HLA-B mole-
cules have the ability to present drug antigens to clonotype-
specific T-cells, supporting the p–i model. On recognizing the
drug antigen-HLA protein complex, T-cells express cytotoxic
proteins (e.g. granulysin) and cytokines (e.g. IL-15), resulting in
extensive skin lesions in SCAR. As viral reactivation was found
in the acute stage of DRESS patients and several viral infections
share the clinical presentation of SJS/TEN (Chiou et al. 2008;
Chung et al. 2013), previous immune history or microbial infec-
tions may contribute to the diversity of the TCR repertoire
(White et al. 2015). Further studies are needed to investigate the
immunological basis of different types of drug hypersensitivity.
The innate immune response: inflammasome activation in
the skin
An important question in understanding the etiology of drug-
induced skin reactions is how APC are activated in the skin.
Contact hypersensitivity is similar to drug-induced skin rashes in
that in both cases many, if not most, appear to involve chem-
ically reactive species. It was found that mice that lack compo-
nents of the inflammasome are resistant to contact
hypersensitivity (Watanabe et al. 2007). Inflammasomes are mul-
timeric protein complexes that are involved in producing an
inflammatory response to pathogen-associated molecular pattern
(PAMP) and DAMP molecules. They convert procaspase-1 to
active caspase-1 that, in turn, converts pro-IL-1b, and pro-IL-18
into their active forms (Man and Kanneganti 2015). The most
studied inflammasome is NLRP3. Inflammasome activation has
been implicated in many chronic diseases including multiple
sclerosis, Alzheimer’s disease, atherosclerosis, and Type 2
diabetes (Guo et al. 2015).
The ability of a drug to activate inflammasomes in macro-
phages appears to predict whether it can cause skin rashes or not
(Weston and Uetrecht 2014). However, the drugs tested had
intrinsic chemical reactivity and could directly activate macro-
phages. Many drugs presumably require metabolic activation,
and most drug-metabolizing enzymes in the skin appear to res-
ide in keratinocytes. Therefore, in most cases, it may be that
various DAMP produced by keratinocytes lead to the activation
of inflammasomes in APC and other macrophages. This, in turn,
could lead to an immune-mediated skin rash in suscep-
tible patients.
Reactive metabolite formation in the skin
Circumstantial evidence suggests that many IDR are due to
reactive metabolites or chemically reactive drugs, such as the
b-lactams. Reactive metabolites can be formed by almost any
metabolic pathway including oxidation, reduction, acetylation,
sulfation, and glucuronida-tion. The metabolic enzymes with the
greatest activity in the skin lead to sulfation and acetylation
(Baron and Merk 2001). Although it is possible that reactive
metabolites formed in the liver or elsewhere could cause an
immune response in the skin, given the short half-life of most
reactive metabolites, it seems most likely that for a reactive
metabolite to cause a skin rash it must be formed in the skin.
For example, the reactive benzylic sulfate of nevirapine is also
formed in the liver and could be detected in the serum of treated
rats. However, inhibition of sulfation in the liver did not prevent
the skin rash while a topical sulfotransferase inhibitor did pre-
vent it (Sharma et al. 2013).
Most reactive metabolites are formed by oxidation, and the
major enzymes involved in the oxidation of drugs to reactive
metabolites are the cytochromes P450 (CYPs). CYP1A1, 1B1, and
2E1 have been identified in Langerhans cells differentiated from
CD34þ cells, adult normal keratinocytes, fibroblasts and melano-
cytes, and CYP2C, 2D6, and 3A5 were identified in fibro-blasts
(Saeki et al. 2002). These results were replicated by a microarray
analysis, in which the CYP1A1, 1B1, and 2E1 were expressed at
comparable levels with the liver (Baron et al. 2008). Additionally,
several other drug-metabolizing enzymes including sulfotransfer-
ases, N-acetyl-transferases, UDP-glucuronosyltransferases, flavin
mono-oxygenase (FMO), and carboxyl-esterases are reported to
be expressed in the skin (Hu et al. 2010). For further extensive
discussion on this subject, please see the review by Sharma
et al. (2013).
Although mRNA coding for various P450 are found in the
skin, the expression of these proteins in the skin is low, and
there are very few examples in which drugs have been shown to
be oxidized to reactive metabolites in the skin. Furthermore,
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most drugs that form P450-mediated reactive metabolites and
cause idiosyncratic liver injury are not associated with a signifi-
cant risk of skin rash though it is much easier to induce an
immune response in the skin than in the liver.
Many drugs associated with IDRs have the potential to form
several reactive metabolites. For example, the skin rash due to
nevirapine is clearly caused by a reactive benzylic sulfate formed
in the skin while most of the covalent binding in the liver
involves the formation of a reactive quinone methide mediated
by P450. Carbamazepine forms a 10,11-epoxide, which is weakly
reactive (Yip et al. 2017). Its phenolic metabolites suggest that it
can also form a 2,3 epoxide. 2-hydroxycarbamazepine can be fur-
ther oxidized to an iminoquinone (Ju and Uetrecht 1999), 3-
hydoxycarbamazepine can be oxidized to a relatively stable free
radical (Lu and Uetrecht 2008), and the glycol metabolite formed
by hydrolysis of the 10,11-epoxide has the potential to form a
benzylic sulfate analogos to that of nevirapine. These pathways
are shown in Figure 1. At present, it is unknown which, if any,
of these potential reactive metabolites is responsible for the IDRs
associated with carbamazepine, which includes TEN. The obser-
vation that polymorphisms in epoxide hydrolase are not associ-
ated with an altered risk in developing carbamazepine-induced
hypersensitivity reactions (including TEN) suggests, but does not
prove, that an epoxide is not responsible for the IDRs associated
with this drug (Green et al. 1995). In addition, although the
10,11-epoxide has a long half-life and can reach the skin, oxcar-
bazepine also causes TEN. The same HLA is a risk factor for
carbamazepine- and oxcarbazepine-induced TEN, but oxcarbaze-
pine cannot form the 10,11-epoxide (Chen et al. 2017). It is pos-
sible that the iminoquinone could be formed in the liver, be
reduced to an aminophenol, and then be re-oxidized in the skin,
as aminophenols are very easily oxidized even by molecu-
lar oxygen.
Other drugs that can redox cycle and are very easily oxidized
are aromatic amines such as sulfamethoxazole, which are associ-
ated with skin rashes. Likewise, 3-hydroxycarbamazepine may be
oxidized by a peroxidase or some other enzyme in the skin.
Finally, the benzylic sulfate of the diol metabolite could be
Figure 1. Possible reactive metabolites of carbamazepine (shown in red), which illustrates how difficult it can be to determine which chemical species is responsible
for a given idiosyncratic drug reaction. The major metabolite of carbamazepine is the 10,11-epoxide. It has a relatively long half-life, and it is easily detected in the
serum of patients taking carbamazepine. However, it is chemically reactive and forms protein adducts. Therefore, it could reach the skin and be responsible for
skin rashes. However, as noted in the text, oxcarbazepine also causes serious skin rashes such as toxic epidermal necrolysis, and the same HLA gene is a risk factor;
however, oxcarbazepine cannot form a 10,11-epoxide. The 10,11-epoxide is hydrolyzed to a diol and this could form a sulfate conjugate, which is a benzylic sulfate
analogous to the sulfate of 12-hydroxynevirapine and predicted to be reactive. Carbamazepine is believed to form a 2,3-epoxide based on the observed 2-, and
3-hydroxycarbamazepine metabolites. However, this epoxide has not been detected in serum and is unlikely to reach the skin in significant concentrations. The
2,3-epoxide could be formed in the skin, but the cytochrome P450 levels in skin are low. The 2-hydroxycarbamazepine can be further oxidized to a reactive iminoqui-
none. This is likely to occur in the liver, but it can redox cycle back to 2-hydroxyiminostibine, which could reach the skin and be easily re-oxidized to the iminoqui-
none. There are many more resonance structures for the free radical of 3-hydroxycarbamazepine than for 2-hydroxycarba-mazepine, and such a free radical could
easily be formed and cause oxidative stress. Either the 2- or 3-hydroxycarbamazepine could be oxidized to a catechol, and this could be further oxidized to a reactive
o-quinone. Carbamazepine can also cause agranulocytosis and aplastic anemia. It is oxidized to an acridine derivative by myeloperoxidase, and this involves a ring
contraction that presumably goes through a reactive carbocation intermediate. Thus there are many candidates for the chemical species that is responsible for serious
carbamazepine-induced skin rashes, and it may be a combination of metabolites or it is also possible that carbamazepine itself could be responsible for causing skin
rashes. (Adapted from Ju and Uetrecht [1999], Lu et al. [2008], and Yip and Pirmohamed [2017]).
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formed analogous to the bioactivation of nevirapine. The fact
that drug, such as carbamazepine, often causes systemic hyper-
sensitivity reactions suggesting that they also form reactive
metabolites outside the skin. Without a valid animal model, it is
very difficult to determine which chemical entity is responsible
for carbamazepine-induced hyper-sensitivity reactions, and dif-
ferent species could be responsible for different IDRs, as appears
to be the case for nevirapine.
Sulfation is an attractive metabolic pathway for the formation
of reactive metabolites in the skin because, unlike with the vari-
ous P450, sulfotransferase activity is high in the skin. One of the
few drugs that causes skin rashes and has been shown to be oxi-
dized by these P450 in the skin is lamotrigine (Chen et al. 2010).
It forms a glutathione conjugate when incubated with keratino-
cytes, and the glutathione conjugate is presumably formed from
an epoxide. However, the reaction constant Km is very high, and
the glutathione conjugate was not detectable unless very high
concentrations of lamotrigine were used. Another metabolite of
lamotrigine is the N-oxide. N-Oxides, such as minoxidil, are sub-
strates for sulfotransferase. The sulfate of lamotrigine N-oxide is
reactive (Lu and Uetrecht 2007), and preliminary evidence sug-
gests that it is formed by human sulfotransferases (unpublished
observation). Presumably IDRs caused by lamotrigine could be
due to the parent drug through the p–i mechanism. Without a
valid animal model, it will be very difficult to test these various
hypotheses. A similar problem may exist for other drugs that
have the potential to form reactive sulfate conjugates.
If, as discussed below, the dominant immune response to
drugs that can cause IDRs is immune tolerance, blocking
immune tolerance may unmask the ability of a drug to cause
skin rashes. A major molecule involved in immune tolerance is
the checkpoint molecule PD-1. Therefore, it may be possible to
develop an animal model using the PD-1/ mouse; however,
the benzylic alcohol of nevirapine is not a substrate for murine
sulfotransferases, and nevirapine does not induce a skin rash
in mice.
Animal models of hypersensitivity reactions
Nevirapine-induced skin rash model
Nevirapine causes skin rash in about 10% of patients treated
with drug; however, in early clinical trials almost everyone devel-
oped a rash when the dose was escalated (Uetrecht: personal
communication). In most patients, the rash is mild; unfortu-
nately, severe rashes such as TEN can occur. Nevirapine also
caused a skin rash in rats; an accidental finding while trying to
identify potential reactive metabolites of nevirapine (Uetrecht,
personal communication). The rash was idiosyncratic in that it
did not occur in male rats, the incidence was about 20% in
female Sprague Dawley rats, but it was 100% in female Brown
Norway rats (Shenton et al. 2003). The rash was clearly immune
mediated as it occurred more rapidly in rats that had been previ-
ously sensitized by treatment with nevirapine, and this sensitivity
could be transferred to naïve rats with lymphocytes from sensi-
tized rats. In addition, depletion of CD4 T-cells prevented rash
(Shenton et al. 2005). The characteristics of rash in rats were
similar to the rash in humans, especially in patients with low
CD4 T-cell count and are at decreased risk, and incubation of
PBMC from patients with a history of nevirapine-induced rash
with nevirapine also resulted in the release of interferon (IFN)-c
(Chen et al. 2009). Therefore, this appears to be a very good ani-
mal model of an IDR, and possibly the only animal model of an
IDR with characteristics similar to that of the IDR in humans
that occurs without manipulation of the immune system.
The nevirapine model also allowed for testing the basis for
the p–i hypothesis. Peripheral mononuclear leukocytes from ani-
mals that have had a nevirapine-induced skin rash were activated
by the parent drug, despite the fact that it is the reactive benzylic
sulfate that induces the rash (Chen et al. 2009). Therefore, what
the lymphocytes from a patient who has had an IDR respond to
in vitro is not necessarily what induced the IDR in the first place,
which suggests that the basis for the p–i hypothesis is false.
Thus, although the in vitro results suggest that nevirapine-
induced skin rash involves the p–i hypothesis, the rash is due to
reactive metabolite. That calls into question other in vitro studies
that have been used to support the p–i hypothesis; therefore, the
p–i hypothesis remains a hypothesis without definitive supportive
evidence. These are two examples of the power of a valid animal
model that made it possible to test hypotheses that would be
virtually impossible to test in humans.
An important factor for developing animal models of IDRs is
immune tolerance
Nevirapine is an exception; other attempts to reproduce adverse
reactions in animals similar to IDRs in humans have failed. In
addition, even though nevirapine can also cause idiosyncratic
liver injury in humans, and Brown Norway rats develop a skin
rash similar to the rash that it causes in humans, the rats did not
develop liver injury. Extensive efforts to develop animal models
based on the current hapten and danger hypotheses have been
unsuccessful. Based on the danger hypothesis, and in addition to
treating animals with drugs that cause IDRs in humans and
covalently bind to hepatic proteins, the Uetrecht labaratory tried
to activate APC through toll-like receptors, for example, lipo-
polysaccharide (LPS) and polyinosinic:polycytidylic acid (poly-
IC). This was done with several drugs, but without success; most
of this work was never published. This is consistent with the
clinical observation that patients with inflammatory conditions
such as ulcerative colitis do not appear to have a higher risk of
IDR. In most cases, the immune system seems to be able to
determine whether the danger signal came from the drug or
some other factor, and only respond to the drug if it is the drug
that caused the injury. Immunizing animals with isoniazid- or
amodiaquine-modified hepatic proteins followed by treatment
with the drug, only led to immune tolerance (Mak and Uetrecht
2015b). This is consistent with the fact that patients with mild
IDRs often have resolution of the IDR despite continued treat-
ment with the drug. If the injury is immune mediated, then the
resolution of the mild injury must involve immune tolerance.
Therefore, if it is immune tolerance that keeps most animals and
humans from having an IDR to a drug that commonly causes
IDR, it might be possible to develop an animal model by inhibit-
ing immune tolerance. In fact, this strategy works. Specifically,
immune checkpoint inhibition using a combination of PD-1/
mice and anti-CTLA-4 antibodies unmasks the potential of drugs
to cause idiosyncratic drug-induced liver injury (Mak and
Uetrecht 2015a; Metushi et al. 2015), and therefore has the
potential to test hypotheses that have not been possible to test in
the past.
In vitro strategies to study immunological drug reactions
Susceptibility to drug hypersensitivity is a function of the chem-
istry of the drug, the genetics of the patient, and environmental
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factors the patient was exposed to at the time of reaction. It is
incredibly difficult to apply each of these factors to an in vitro
cell system; as such there are no currently no assays available for
predicting drug immunogenicity. The purpose of this section of
the article is to provide a brief summary of what is known about
drug-specific T-cell responses and how this knowledge is being
used to develop novel T-cell priming assays that may in the
future be used to screen for drug immunogenicity and skin
sensitization.
Whenever possible T-cells isolated from blood and tissues of
hypersensitive patients should be used to investigate the cellular
pathophysiology of the adverse event and the way in which drugs
interact with immune receptors (major histocompatibility com-
plex [MHC] and the T-cell receptor [TCR]), as with these cells
one can reimagine in vitro the relevant drug immune cell inter-
actions. As discussed earlier, the discovery of strong associations
between expression of single HLA alleles and susceptibility to
drug hypersensitivity has changed the way in which we view
hypersensitivity reactions to drugs; they are no longer totally
unpredictable. As such, it is important that all mechanistic stud-
ies use cells from HLA-typed patients alongside a battery of in
vitro assays to characterize the effects of drug treatment on DC
signaling and the activation of cells of the adaptive immune sys-
tem. Moreover, state-of-the-art mass spectrometers should be
available to study the metabolism of drugs in in vitro culture sys-
tems, characterize and quantify the binding of drug metabolites
to protein, and relate the chemistry of adduct formation to the
biological response (i.e. activation of T-cells). Figure 2 illustrates
a research strategy that could be applied to study drug hypersen-
sitivity using patient cells.
Activation of hypersensitive patient T-cells with drugs
Several drugs are directly protein-reactive, while others gain pro-
tein reactivity through drug metabolism. Reactive drugs bind
covalently to nucleophilic amino acid residues on proteins to
form adducts that, following protein processing, yields MHC
binding peptides that activate T-cells (Meng et al. 2017). APC
express low levels of drug metabolizing enzymes, when compared
with hepatocytes; however, the levels of adducts formed from
some drugs have been shown to be sufficient to bind to protein
and form adducts that activate T-cells (Elsheikh et al. 2011).
Reactive drug metabolites in in vitro culture also bind directly to
MHC bound peptides to activate T-cells (Schnyder et al. 2000;
Castrejon et al. 2010). Whether this represents an in vitro artifact
mimicking a naturally processed protein adduct is currently not
known. Drugs can also interact with MHC and T-cell recep-
tors directly.
Classical studies demonstrated that T-cell receptors can be
triggered with drugs rapidly (within minutes) through a pathway
that does not require protein processing (Schnyder et al. 1997;
Zanni et al. 1998). Abacavir has been shown to bind deep within
the MHC peptide binding cleft, altering the space available for
peptides to bind (Illing et al. 2012; Norcross et al. 2012; Ostrov
et al. 2012). As such, a novel repertoire of peptides interact with
the abacavir-modified MHC molecules, and it is believed that
Figure 2. Drug hypersensitivity research strategy. Drug hypersensitivity research strategy using PBMC from hypersensitive patient and healthy volunteers. Patient
PBMC are used directly in diagnostic tests and for mechanistic studies to assess antigen specificity and mechanisms of HLA allele-restricted T-cell activation. PBMC
from volunteers are used to investigate the priming of naïve T-cells to drugs and drug metabolites. It is important that samples are collected from all immunological
investigations to explore the cellular distribution of drugs and the irreversible binding of drugs to protein.
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T-cells responsible for abacavir hypersensitivity are triggered by
these peptide sequences. For all other drugs shown to activate T-
cells directly (e.g. sulfa-methoxazole [Schnyder et al. 1997], oxy-
purinol [Yun et al. 2013], lamotrigine [Naisbitt et al. 2003]), the
nature of the MHC binding interaction has not been defined.
Development of assays to study the priming of naïve T-cells
Studies utilizing hypersensitive patient T-cells are important, but
they tell nothing about the origin of the drug-specific T-cell
response. For this reason, researchers at the Medical Research
Council (MRC)-funded Liverpool Centre for Drug Safety Science
have spent 5 year developing cellular platforms using PBMC from
healthy drug-naïve volunteers to study T-cell priming. The follow-
ing section details the evolution of such assays, their current appli-
cation domain and how further development might result in in
vitro test systems to predict the intrinsic immunogenicity of new
compounds. The availability of such assays is important as hyper-
sensitivity often fails to be detected until post-marketing. As such,
hypersensitivity reactions are a leading cause for drug withdrawal,
resulting in patients needing to wait until an alternative is brought
to the market (Negrini and Becquemont 2017).
Newman et al. (1977) were the first to report that human
lymphocytes could be primed in vitro against chemical sensi-
tizers. Subsequently, Seldin and Rich (1978) devised an in vitro
system to study both primary and secondary responses of lym-
phocytes to hapten-conjugated proteins. Co-culture of lympho-
cytes with hapten-modified PBMC resulted in antigen-specific
proliferative responses. The method has been modified in several
subsequent studies; specifically, different forms of DC have been
used as APC with naïve T-cells as responders. This allowed for
discrimination of strong sensitizers from irritants. However,
weak sensitizers failed to activate T-cells. In recent years,
improved protocols have been used to generate DC, and T-regu-
latory (Treg) cells have been removed from responders to
enhance sensitivity. Furthermore, multiple readouts are now
available to detect the antigen-specific T-cell responses (Dietz
et al. 2010; Martin et al. 2010).
Researchers at Liverpool developed methods to study the ori-
gin of drug- and drug metabolite-specific T-cell responses in
healthy donors (Faulkner et al. 2012, 2016; Monshi et al. 2013).
The assay relies on isolation and culture of autologos monocyte-
derived DC and naive T-cells as APC and responder cells,
respectively. After a 7–10 d culture period, T-cells are re-exposed
to the drug antigen and DC before antigen specificity is meas-
ured shortly after. In addition to classical readouts for prolifer-
ation, cytokine secretion and cytotoxicity, a change in phenotype
from naive T-cell to memory T-cell is quantified by flow cytome-
try. Strong responses are detected to haptenic drug metabolite(s),
such as piperacillin and nitroso sulfamethoxazole (Faulkner et al.
2016). T-Cell priming is also detected against direct MHC bind-
ing drug metabolite(s), including sulfamethoxazole, carbamaze-
pine, and oxypurinol. The platform is flexible in that it can be
used to study (1) the phenotype of activated T-cells, (2) HLA-
allele-restricted forms of hypersensitivity, (3) immune regulation,
and (4) tissue-specific signaling, as briefly discussed below.
Immune cells activated by drugs
Chemically distinct drugs and metabolites have been shown to
prime naïve T-cells, produce polarized cytokine secretion profiles
following re-stimulation and display selective chemokine migra-
tion properties (Faulkner et al. 2012, 2016). In contrast, abacavir
preferentially activates pre-existing memory T-cells from healthy
donors that must have been primed by earlier exposure to
another foreign antigen (Lucas et al. 2015). Most recently, focus-
ing on sulfamethox-azole, we have shown that naïve and mem-
ory T-cells from healthy donors can be stimulated by parent
drug and drug metabolites (Gibson et al. 2017). These data high-
light the need to study naïve and memory T-cell populations.
HLA alleles
Several strong associations between susceptibility to specific
forms of immunological drug reaction and expression of HLA
alleles have been identified. For certain drugs, it has been pos-
sible to relate the genetic association to the disease by showing
that T-cells are selectively activated in individuals expressing the
risk allele. To study the propensity of drugs to initiate T-cell
responses, it is critical to work with genetically characterized
cells. For this to be feasible, the Naisbitt laboratory has estab-
lished a unique HLA genotyped cell bank containing 100 mil-
lion PBMC from 1000 healthy donors.
Immune regulation
Most HLA associations with drug hypersensitivity have a low
prognostic value (e.g. HLA-B57:01 is associated with flucloxacil-
lin-induced liver injury, but only 1/1000 HLA-B57:01-express-
ing individuals develop hypersensitivity). Therefore, additional
immunological parameters are involved in regulating the activa-
tion of drug-specific T-cells. Co-stimulatory and co-inhibitory
pathways signal simultaneously to regulate whether antigen
exposure will lead to T-cell activation. Thus, it is conceivable
that dysregulation of these pathways may manipulate the thresh-
old of T-cell activation to such an extent that they enhance a
patient’s susceptibility to drug hypersensitivity. Indeed, an inhibi-
tory role for the PD-1 and CTLA-4 pathways during the priming
of naïve T-cells to drugs has been reported (Gibson et al. 2014,
2017). As research moves forward, it will be crucial to elucidate
the effect of modulation of multiple cosignaling pathways
together to effectively analyze the role of inhibitory signaling
during T-cell activation.
Tissue microenvironment
A limitation of existing T-cell priming assays is that immune
cells are exposed to drugs directly or conjugated to a carrier pro-
tein. Assay development is complicated by the fact that many
drugs are not directly protein-reactive, and as such, antigenic
determinants are not always generated in the assay. Furthermore,
the cross-talk between tissue and immune cells is important in
determining the outcome of compound exposure. For example,
hepatocytes treated with model hepatotoxins release signals that
promote the secretion of polarizing cytokines from DC (Ogese
et al. 2017). Thus, new strategies need to be developed to
enhance exposure of immune cells to relevant tissue-specific
stress signaling and tissue-derived drug-protein adducts.
Development of a tissue/immune cell culture system has been a
challenge for the investigation of drug immuno-genicity in
humans as autologous cells are required. One way to overcome
this shortcoming will be the generation of induced pluripotent
stem cells (iPS)-derived keratinocyte lines and antigen-specific
T-cells from the same donors expressing an important HLA
risk allele.
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Development of screening assays
Existing T-cell priming assays are still far from perfect. A major
drawback is the experimental design, which is time-consuming
and is more suited for laboratory-based investigation of a few
variables. As such, they cannot currently be used to screen new
compound for the potential to cause immune responses when
administered to humans. A reason for this is the absence of
medium/high throughput assays. Efforts to transform existing
assays into suitable platforms for the screening of drugs are
focused on miniaturization to assess (1) multiple HLA-typed
individuals simultaneously and (2) multiple experiments with
cells from one individual. The eventual transfer of such assays to
industrial partners provides a pathway for assessment of
immunogenicity of novel drugs and for initial application of the
newly established methods.
Conclusions
Skin rashes continue to represent a significant clinical problem,
and our mechanistic understanding is superficial. A simplified
scheme of a reasonable hypothesis for the mechanism of serious
skin rashes is shown in Figure 3. The components of this
hypothesis should be tested, and the only practical way to do
this is by developing valid animal models that replicate the meta-
bolic pathways in humans to accurately predict which drug can-
didates are likely to pose a significant risk of serious skin rashes.
Even though the skin is less tolerogenic than most organs, the
dominant immune response to drugs that can cause skin rashes
in humans appears to be immune tolerance. Therefore, it may be
possible to develop animal models of skin rashes by impairing
immune tolerance. However, it is necessary that the animal has
the same metabolic pathways as humans; this is not the case for
the formation of a reactive sulfate metabolite of nevirapine in
mice. With such models, it might be possible to predict as to
which drug candidates are likely to pose a significant risk of
serious skin rashes.
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